Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801021 · ClinicalTrials.gov registry record · Phase 1
Treatment and/or Prevention of Urinary Tract Infections
A Phase 1 study of Urinary Tract Infections and Cystitis, sponsored by Biomedical Development Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT00801021 is a Phase 1 study of Urinary Tract Infections and Cystitis that has completed, run by Biomedical Development Corporation. The registered enrollment target is 3 participants, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00801021, a Phase 1 study of Urinary Tract Infections and Cystitis, has completed, sponsored by Biomedical Development Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the effect of an investigational oral rinse in reducing uropathogens and treating uncomplicated urinary tract infections.
Conditions Studied
Interventions
- DRUG Frio Mouth Rinse
Study Locations (1)
Texas
- Ben Taub General Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00801021
The ClinicalTrials.gov registry entry for NCT00801021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (99% lower). The listed sponsor is Biomedical Development Corporation, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Urinary Tract Infections appearing as the primary indexed condition, and to 1 intervention - of which Frio Mouth Rinse is the first listed.
NCT00801021 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00801021 about?
NCT00801021 is a clinical study titled "Treatment and/or Prevention of Urinary Tract Infections". The purpose of the study is to determine the effect of an investigational oral rinse in reducing uropathogens and treating uncomplicated urinary tract infections.
What is the current status of trial NCT00801021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-12. Estimated completion is 2009-06.
What conditions does trial NCT00801021 study?
This clinical trial studies the following conditions: Urinary Tract Infections, Cystitis.
What interventions are being tested in trial NCT00801021?
The interventions under investigation include: Frio Mouth Rinse (DRUG).
Who is sponsoring clinical trial NCT00801021?
This trial is sponsored by Biomedical Development Corporation, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00801021 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
RECRUITING · Phase 1
-
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
COMPLETED · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
NextGen - Clinical Implication of Next Generation Sequencing
RECRUITING · Phase 4
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.